Comparing Effects of Various Combinations of 6 Hertz(Hz) rTMS & LFrTMS on Motor Recovery Due to Cerebrovascular Disease

Sponsor
Beijing Hospital (Other)
Overall Status
Unknown status
CT.gov ID
NCT03012204
Collaborator
(none)
120
1
4
21.5
5.6

Study Details

Study Description

Brief Summary

To compare the effects of various combinations between 6 hertz(Hz) rTMS & LFrTMS on the limb motor dysfunction due to cerebral vascular disease.

Condition or Disease Intervention/Treatment Phase
  • Device: real LFrTMS at unaffected M1
  • Device: real primed LFrTMS at unaffected M1
  • Device: combined rTMS at both M1
  • Device: all sham stimulation
N/A

Detailed Description

It is the basic principle for functional recovery after cerebrovascular disease to restore the original balance in reciprocal inhibition between affected hemisphere and unaffected hemisphere.

repetitive transcranial magnetic stimulation (rTMS) is a noninvasive neuroplastic technique rebalancing interhemispheric competition after stroke. Low frequency rTMS (LFrTMS) on contralesional hemisphere or high frequency rTMS (HFrTMS) on lesional hemisphere might be the basic choice.

6 hertz(Hz) primed LFrTMS on lesional primary motor cortex has the stronger effect than LFrTMS alone does on one hand; the other newly-developed combination, i.e. HFrTMS on lesional primary motor cortex and LFrTMS on contralesional primary motor cortex might also be more effective than they do respectively on the other hand.

The main aim of our research is to find out which combination is better by considering both safety and efficiency.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
120 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
Double (Participant, Outcomes Assessor)
Primary Purpose:
Treatment
Official Title:
Series Study About the rTMS Effects on the Recovery of Limb Motor Dysfunction Due to Cerebral Vascular Disease, Part 1: Comparing the Effects of Various Combinations Between 6 Hertz(Hz) rTMS & LFrTMS.
Actual Study Start Date :
Feb 16, 2017
Anticipated Primary Completion Date :
Dec 1, 2018
Anticipated Study Completion Date :
Dec 1, 2018

Arms and Interventions

Arm Intervention/Treatment
Experimental: combined rTMS at both M1

combined rTMS at both M1: sham 6 hertz(Hz) rTMS on unaffected M1 / real 1 Hz rTMS on unaffected M1 / real 6 Hz rTMS on affected M1

Device: combined rTMS at both M1
Compare the effect of combined rTMS at both M1 to that of primed LFrTMS at unaffected M1 on motor rehabilitation after cerebrovascular disease . rTMS: Repetitive Transcranial Magnetic Stimulation. Combination Elements: ①6 hertz(Hz) rTMS at unaffected M1 before LFrTMS at unaffected M1 ;②6 Hz rTMS at affected M1;③1 Hz rTMS at unaffected M1. The four groups are the combinations of real or sham ①/②/③.

Experimental: real primed LFrTMS at unaffected M1

real primed LFrTMS at unaffected M1: real 6 hertz(Hz) rTMS on unaffected M1 / real 1 Hz rTMS on unaffected M1 / sham 6 Hz rTMS on affected M1

Device: real primed LFrTMS at unaffected M1
Compare the effect of primed LFrTMS at unaffected M1 to that of LFrTMS at unaffected M1 on motor rehabilitation after cerebrovascular disease . rTMS: Repetitive Transcranial Magnetic Stimulation. Combination Elements: ①6 hertz(Hz) rTMS at unaffected M1 before LFrTMS at unaffected M1 ;②6 Hz rTMS at affected M1;③1 Hz rTMS at unaffected M1. The four groups are the combinations of real or sham ①/②/③.

Active Comparator: real LFrTMS at unaffected M1

real LFrTMS at unaffected M1: sham 6 hertz(Hz) rTMS on unaffected M1 / real 1 Hz rTMS on unaffected M1 / sham 6 Hz rTMS on affected M1

Device: real LFrTMS at unaffected M1
Compare the effect of LFrTMS at unaffected M1 to that of all sham stimulation on motor rehabilitation after cerebrovascular disease . rTMS: Repetitive Transcranial Magnetic Stimulation. Combination Elements: ①6 hertz(Hz) rTMS at unaffected M1 before LFrTMS at unaffected M1 ;②6 Hz rTMS at affected M1;③1 Hz rTMS at unaffected M1. The four groups are the combinations of real or sham ①/②/③.

Sham Comparator: all sham stimulation

all sham stimulation: sham 6 hertz(Hz) rTMS on unaffected M1 / sham 1 Hz rTMS on unaffected M1 /sham 6 Hz rTMS on affected M1

Device: all sham stimulation
used as controls to eliminate the placebo effect of all kinds of combinated rTMS

Outcome Measures

Primary Outcome Measures

  1. Fugl-Meyer assessment (FMA) [1) Before treatment (Baseline); 2) Change from Baseline FMA at the 1st workday after the last treatment; 3) Change from Baseline FMA at the 28th natural day after the last treatment]

    Score of Fugl-Meyer assessment

  2. Simple Test for Evaluating Hand Function (STEF) [1) Before treatment (Baseline); 2) Change from Baseline STEF at the 1st workday after the last treatment; 3) Change from Baseline STEF at the 28th natural day after the last treatment]

    Score of Simple Test for Evaluating Hand Function

Secondary Outcome Measures

  1. National Institute of Health Stroke Scale (NIHSS) [1) Before treatment (Baseline); 2) Change from Baseline NIHSS at the 1st workday after the last treatment; 3) Change from Baseline NIHSS at the 28th natural day after the last treatment]

    Score of National Institute of Health Stroke Scale

Eligibility Criteria

Criteria

Ages Eligible for Study:
30 Years to 90 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Aged from 30 to 90 years;

  • Newly onset cerebral infarction or brain hemorrhage confirmed by MRI or CT;

  • the disease duration is less than 20 weeks when recruited into the trial;

  • no existence of limb motor dysfunction before this onset, and new occurrence of unilateral limb motor dysfunction after this onset;

  • the physical and mental condition are good enough to cooperate with the assessment and treatment;

  • the NIHSS score: total 5-20,1a,1b,1c=0;

  • the subject or legal guardian sign the consent form.

Exclusion Criteria:
  • during pregnancy;

  • with skull defect;

  • with metal implants, cardiac pacemaker, cochlear implantation;

  • epileptiform discharge in EEG.

Contacts and Locations

Locations

Site City State Country Postal Code
1 Beijing Hospital, National Center of Gerontology Beijing Beijing China 100730

Sponsors and Collaborators

  • Beijing Hospital

Investigators

  • Principal Investigator: Li Zhuang, M.D., Beijing Hospital, National Center of Gerontology, China

Study Documents (Full-Text)

None provided.

More Information

Publications

Responsible Party:
ZHUANG Li, MD, Chief Physician, Beijing Hospital
ClinicalTrials.gov Identifier:
NCT03012204
Other Study ID Numbers:
  • 121-2016010
First Posted:
Jan 6, 2017
Last Update Posted:
Mar 15, 2017
Last Verified:
Mar 1, 2017
Individual Participant Data (IPD) Sharing Statement:
Undecided
Plan to Share IPD:
Undecided
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by ZHUANG Li, MD, Chief Physician, Beijing Hospital
Additional relevant MeSH terms:

Study Results

No Results Posted as of Mar 15, 2017